TOC |
ENDO
Pheochromocytoma
SX |
DX | RX |
Diff-Dx
Consider pheochromocytoma if the hypertensive patient has the triad
of headache, sweating, & palpitations. Although rare
(0.1% of hypertensive patients), pheochromocytoma is a life-threatening but
potentially curable condition. Over 90% of patients with pheochromocytoma
have hypertension, and over half have sustained elevations of blood pressure.
Pheochromocytomas are chromaffin cell tumors that, although rare,
must be considered in patients with hypertension, autonomic disturbances,
panic attacks, adrenal incidentalomas, or familial diseases featuring
a predisposition to develop pheochromocytoma.
Use history findings to determine the need for
biochemical testing for pheochromocytoma. * Consider evaluating
patients with:
-
Refractory hypertension
-
Hypertension (sustained or intermittent
hypertension. Orthostatic drop in blood pressure is frequently present),
accompanied by hyperadrenergic spells
with: + Nonexertional palpitations (Patients
may describe this as more of a forceful heartbeat rather than
tachycardia; may occur in isolation or as part of the paroxysm) +
Diaphoresis (May be a drenching
sweat; usually part of stereotypic spell) +
Headache (Typically a pounding
type headache that occurs with the paroxysm) +
Tremor (Fine
tremorsimilar to that seen with hyperthyroidism) +
Pallor (Patients may feel
flushed, but are actually pale)
-
Family history of familial pheochromocytoma
-
A genetic syndrome that increases the risk of pheochromocytoma, such as:
+ Multiple endocrine neoplasia type 2 + von Hippel-Lindau disease +
Neurofibromatosis type 1
-
History of gastric stromal tumor or pulmonary chondromas (Carney triad)
-
An incidentally discovered adrenal mass
SX:
-
Hypertension - paroxysmal or sustained is the most common clinical
sign. May have paradoxical response to antihypertensive Rx as Beta-blockers
or guanethidine.
-
Headaches occur in over 90% of patients with paroxysmal hypertension
and in 70% with sustained hypertension. They are typically throbbing in
character, most often occipital or frontal and are frequently accompanied
by nausea and vomiting.
-
Sweating occurs in 60-70% of patients and is often greater in the
upper portion of the body.
-
Palpitations, with or without tachycardia, occur in patients
with sustained (51%) or paroxysmal (73%) hypertension.
-
Some patients present with severe episodes of anxiety, nervousness, or
panic.
-
Nausea, vomiting, and epigastric pain are relatively common. Impaired
intestinal motility and constipation are common, and ischemic enterocolitis,
intestinal obstruction, and megacolon have been observed.
-
The incidence of cholelithiasis is increased in pheochromocytoma for
unknown reasons.
-
Vasoconstrictive effects of catecholamines in the extremities can
cause pain, paresthesias, intermittent claudication, Raynaud phenomenon,
ischemia, and ulceration. Pallor is also common, whereas flushing
occurs less frequently.
Determine the need for pheochromocytoma testing
with physical exam or imaging studies. Look for:
-
* Hypertension * Orthostatic hypotension * Hypertensive retinopathy (grade
III to IV) * Marfanoid body habitus * Café au lait spots
(Neurofibromatosis) * Axillary freckling * Subcutaneous neurofibromas
* Mucosal neuromas on eyelids and tongue * Retinal angiomas
-
Consider testing for pheochromocytoma in all patients with an adrenal mass
found on CT.
Lab. tests for suspected pheochromocytoma
Consider measurement of metanephrines and catecholamines in a 24-hour urine
collection and metanephrines in blood for patients with suspected
pheochromocytoma.
-
Measure 24-hour urinary metanephrine excretion
if clinical suspicion for pheochromocytoma is low; for example,
in the asymptomatic patient with:
* New onset, stage 1 hypertension * An incidentally discovered adrenal mass
with findings on CT that are consistent with a benign cortical adenoma
-
Measure 24-hour urinary excretion of metanephrines
and catecholamines and plasma
metanephrines if clinical suspicion is high
(start the 24-hour urine collection with the onset of a spell, if possible.)
24-hour urinary total metanephrines - Sensitivity 76-95%,
Specificity 94-99%.
-
24-hour urinary total metanephrines >1.3 mg in a patient not taking an
interfering medication and not physically stressed is consistent with
pheochromocytoma
24-hour urinary catecholamines - Sensitivity 77-95%, Specificity
79-99%
-
24-hour urinary total norepinephrine and epinephrine levels more than 2-fold
increased above the ULN for the assay in a patient not taking an interfering
medication and not physically stressed is consistent with pheochromocytoma
Plasma metanephrines - Sensitivity 99-100%, Specificity
85-89%
-
Plasma normetanephrine and metanephrine levels >50% increased above the
ULN for the assay in a patient not taking an interfering medication and not
physically stressed is consistent with pheochromocytoma
Plasma catecholamines - Sensitivity 85%, Specificity 80%
-
Plasma catecholamines (norepinephrine + epinephrine) drawn in a supine rested
patient with an indwelling canula increased to values >2,000 pg/mL are
consistent with pheochromocytoma
CT abdominal scan - Sensitivity 93-100%, Specificity 50%
-
Sensitivity is excellent for adrenal pheochromocytoma and less for extra-adrenal
catecholamine-secreting tumors. Specificity is poor due to the high prevalence
of adrenal cortical adenomas
MRI abdominal scan - Sensitivity 93-100%, Specificity 75%
-
Sensitivity is excellent for adrenal pheochromocytoma and less for extra-adrenal
catecholamine-secreting tumors. Specificity is improved over CT due to the
high signal intensity of pheochromocytomas on T-2 weighted imaging
123I-MIBG scintigraphy - Sensitivity 80%, Specificity 99%
-
MIBG (metaiodobenzylguanidine) scintigraphy is very specific; however, the
sensitivity is less than computerized imaging
-
At this time, however, 15% of tumors are not recognized by this technique
and only 50% of malignant pheochromocytomas appear to concentrate
131I.
Central venous blood sampling
-
Central venous blood sampling of catecholamines can assist in localization
of the tumor when all other means fail. However, this procedure is not perfected
in all centers.
DX:
* Plasma free metanephrines provide the best test
for exluding or confirming pheochromocytoma & should be the test of first
choice for diagnosis of the tumor.
JAMA
March 20, 2002;287:1427 Jacques W. Lenders, etc
Diagnosis of pheochromocytoma usually requires biochemical evidence of excessive
catecholamine production by the tumor, usually achieved from measurements
of catecholamines or catecholamine metabolites in urine or plasma. These
biochemical approaches, however, have several limitations.
-
Plasma nor-metanephrine > 2.5
pmol/mL or metanephrine >
1.4 pmol/mL (more than 4- and 2.5-fold above the upper reference
limits) indicate a pheochromocytoma with 100% specificity.
Resting plasma catecholamine (Norepinephrine & Epinephrine) levels
> 2,000 pg/mL
-
Urinary total metanephrine levels > 1.8 mg/24
hours. Urinary norepinephrine levels > 156 ug/24
hours
Since catecholamines are normally produced by sympathetic nerves and by the
adrenal medulla, high catecholamine levels are not specific to pheochromocytoma
and may accompany other conditions or disease states. In addition, sometimes
pheochromocytomas do not secrete enough catecholamines to produce positive
test results or typical signs and symptoms. In addition, pheochromocytomas
often secrete catecholamines episodically. Between episodes, levels of
catecholamines may be normal. Thus, commonly used tests of plasma or urinary
catecholamines and metabolites and other biochemical tests, such as measurements
of plasma chromogranin A levels, do not always reliably exclude or confirm
a tumor. A recently developed biochemical test, involving
measurements of plasma levels of free
metanephrines (o-methylated metabolites of catecholamines),
circumvents many of the above problems and offers a more effective means
to diagnose pheochromocytoma than other tests .
A. Plasma catecholamine measurement, as plasma free metanephrines
Plasma concentrations of normetanephrine greater
than 2.5 pmol/mL or metanephrine levels greater than 1.4 pmol/mL (more than
4- and 2.5-fold above the upper reference limits) indicate a pheochromocytoma
with 100% specificity.
As with all biochemical tests, high plasma levels of normetanephrine or
metanephrine do not necessarily prove a pheochromocytoma.
Most patients with pheochromocytoma can be identified
immediately by a single test of plasma metanephrines.
Many patients have marginally elevated plasma levels of normetanephrine or
metanephrine. Among this group, differentiating true-positive from false-positive
results remains a problem. Additional follow-up biochemical tests should
include measurements of plasma catecholamines and repeated measurements of
metanephrines. Since metanephrines are produced continuously by a
pheochromocytoma, normal plasma levels of normetanephrine and metanephrine
in a second test exclude pheochromocytoma, even if results of the first test
or other tests are positive. If plasma metanephrines remain positive, then
the pattern of alterations in other results can be helpful in planning a
strategy for further testing, as the clonidine suppression test.]
Conclusion: Plasma free metanephrines provide the best test
for excluding or confirming pheochromocytoma and should be the test of first
choice for diagnosis of the tumor.
JAMA
March 20, 2002;287:1427 - Jazques Lenders, etc.
-
Plasma catecholamine measurement is being
increasingly used because blood can be collected before and immediately after
an attack (whether spontaneous or provoked). However, conditions such as
anxiety, volume depletion, acidosis, hypotension, anoxia, exercise, smoking,
renal failure, increased intracranial pressure, marked obesity, and drugs
such as L-dopa, methyldopa, histamine, and glucagon can elevate plasma
catecholamines in the absence of pheochromocytoma. If this method is used,
the patient should have an indwelling catheter placed and rest supine for
at least 30 minutes prior to sample collection.
B. Total metanephrine & normetanephrine in 24-hour urine specimen
-
It is the most reliable screening test, since more than 95% of patients
with pheochromocytoma have increased total metanephrines. A single voided
(spot) urine metanephrine level correlates closely with the results of the
24-hour urine collection and is particularly useful when collected following
an attack. False-positive results are infrequent but can be seen in patients
taking chlorpromazine, benzodiazepines, or sympathomimetics.
C. Urinary free catecholamines
-
Urinary free catecholamines (norepinephrine, epinephrine, and dopamine) are
measured to confirm the diagnosis of pheochromocytoma in patients with elevated
metanephrine or vanillylmandelic acid (VMA) levels. Measurement of fractionated
catecholamines is also particularly useful if only epinephrine or dopamine
is secreted.
D. Urinary VMA
-
Urinary VMA is readily available but the least reliable due to the
high incidence of false-negatives and false-positives. Many drugs and food
products are known to interfere with this assay.
E. Provocative and suppression tests
These tests are useful if the laboratory studies are inconclusive.
1. The clonidine suppression test differentiates pheochromocytoma
from essential hypertension in patients exhibiting elevated norepinephrine
levels. Administration of 0.3 mg clonidine will suppress norepinephrine
into the normal range within 3 hours after administration in essential
hypertension patients but not in patients with pheochromocytoma. False-negatives
and false-positives have been reported.
The clonidine suppression test is useful for distinguishing between high
levels of plasma norepinephrine caused by release from sympathetic nerves
and those caused by release from a pheochromocytoma. A decrease of more
than 50% in plasma norepinephrine levels or a decrease after clonidine
administration to less than 2.96 nmol/L indicate normal responses, whereas
consistently elevated concentrations before and after clonidine administration
indicate a pheochromocytoma. When the above criteria for a normal response
are used, the test is highly specific. However, in patients with intermittently
secreting tumors or those in whom plasma norepinephrine concentrations are
normal or only marginally elevated, plasma norepinephrine levels may decrease
regardless of a tumor, resulting in a false-negative test result. False-positive
test results can occur in patients taking diuretics or tricyclic antidepressants.
However, except in these cases, clonidine rarely fails to decrease plasma
norepinephrine levels in patients without
pheochromocytoma.
** Severe hypotensive episodes may occur during the test. The test
should be done by experienced clinician.
2. Pentolinium, a preganglionic-blocking agent, when administered in a dose
of 2.5 mg, causes a drop in catecholamine levels in patients without
pheochromocytoma. Since pheochromocytomas do not have a preganglionic nerve
supply, no change is seen in catecholamine levels in these patients.
3. Glucagon and histamine can be used to provoke attacks but are associated
with side effects as well as pressor crisis. Both glucagon and histamine
are limited by false-positive and false-negative responses. If these agents
are used, phentolamine should be available for administration in a dosage
of 2.5 mg IV q5min should a pressor hypertensive crisis occur.
The glucagon stimulation test can be useful when high plasma levels
of normetanephrine or metanephrine are noted and plasma catecholamine levels
are normal or moderately elevated. A greater than threefold increase in
norepinephrine levels 2 minutes after intravenous administration of glucagon
indicates a pheochromocytoma with high specificity. However, the test is
not sensitive, and a negative test result does not exclude
pheochromocytoma.
** Severe hypertensive episodes may occur during the test, and it should
be done by experienced clinicians.
Differential Diagnosis of Elevated plasma
catecholamine & urin. metanephrine levels:
-
Acute clonidine withdrawal
-
Acute alcohol withdrawal
-
Vasodilator Rx with hydralazine or minoxidil
-
Acute myocardial ischemia or infarction
-
Acute cerebrovascular accident (stroke)
-
Cocaine abuse
-
Severe CHF
-
IV dopamine, dopaminergic drugs, and acute hypoglycemia
-
Phenylpropanolamine abuse
RX:
Surgical excision of the tumor
(adrenalectomy) is the definitive
treatment for pheochromocytoma,
Surgery for pheochromocytoma entails several considerations. Induction of
anesthesia before surgery, manipulation of the tumor, or other stimulation
can cause massive outpouring of catecholamines from the tumor, resulting
in hypertensive crisis, stroke, arrhythmias, or myocardial infarction. To
prevent these problems, patients with pheochromocytoma must undergo pharmacologic
blockade of catecholamine synthesis or effects before surgery.
Preoperative therapy should precede surgery by at least 1-2 weeks to allow
for volume repletion and the return of normal baroreflex function.
Many centers do not employ preoperative alpha blockade in patients who are
clinically stable, and complete blockade is contraindicated because the surgeon
will be unable to guide surgical removal by blood pressure response to palpation
in the vicinity of the tumor.
The combination of metyrosine, phenoxybenzamine,
a Beta-blocker, and liberal salt intake starting 10 to 14 days before
surgery leads to better control of blood pressure and decreases
surgical risks. Combined medical blockade also allows relaxation of the
constricted vascular tree and expansion of the reduced plasma volume, thus
avoiding shock after sudden diffuse vasodilation at the time of tumor removal.
At midnight before surgery, the patient receives phenoxybenzamine and metyrosine
and is assigned to bedrest to avoid orthostatic hypotension. Intravenous
fluids are administered for hydration and to ensure adequate blood volume.
After adequate medical blockade and hydration, surgical excision of
pheochromocytoma has been performed through a transabdominal incision, with
palpation of the contralateral adrenal gland and sympathetic chain to identify
possible additional tumors. Patient survival rates of 97.7% to 100% are usual
after such procedure.
Steroid "replacement" therapy after bilateral adrenalectomy often does not
suffice for normalizing quality of life. Between 25% and 33% of patients
undergoing bilateral adrenalectomy develop Addisonian crisis at some point,
and attendant mortality rates are high. Moreover, 30% of patients develop
clinically significant fatigue, and 48% consider themselves handicapped.
In patients with pheochromocytoma, partial adrenalectomy can preserve
adrenocortical function and avoid the morbidity of medical adrenal replacement.
Postoperative follow-up of patients with sporadic and familial forms of
pheochromocytoma includes evaluation of plasma metanephrine levels at
approximately 6 weeks and again at 6 months after surgery. Because of the
high rate of tumor recurrence in familial pheochromocytoma, we recommend
yearly follow-up in these patients. Imaging studies should be performed on
the basis of follow-up test results.
[Dr. Y.I.C. - I usually give Dybenzyline
(Phenoxibenzamine) 10 mg bid for 10 days prior to surgery and
give about 60 to 70 mg at midnight before of the surgery. Perioperative
management demands expert anesthesiologic care, sometimes pt. may require
8 to 12 liters of fluid in 24 hrs after the tumor is out. ]
Recognize the importance of drug preparation in
maximizing chances of a successful surgical outcome.
-
Administer both alpha-adrenergic and beta-adrenergic blockers preoperatively.
C
-
Consider long-acting, calcium channel blockade or tyrosine hydroxylase inhibition
if alpha-adrenergic and beta-adrenergic blocking agents are ineffective or
poorly tolerated. C
-
Treat acute hypertensive crises with intravenously administered agents. C
-
Consider treatment in patients with malignant or unresectable disease with
tumor-directed therapy in addition to the previously outlined drug therapy
with alpha-adrenergic blocker, beta-adrenergic blocker, and/or a calcium
channel blocker.
A. Acute medical therapy
In the patient with severe hypertension or other dramatic symptoms in whom
pheochromocytoma is known or suspected, acute therapy includes the following:
-
Bed rest with the head of the bed elevated.
-
Alpha-receptor blockade can be achieved with phentolamine, 2-5 mg IV
q5min until blood pressure is stabilized.
-
Sodium nitroprusside (100 mg in 500 ml dextrose as an infusion) can
be titrated to control blood pressure.
-
Beta blockade can be used to control arrhythmias only after alpha
blockade has been achieved.
Propranolol (1-2 mg IV every 5-10 minutes) or esmolol (0.5 mg/kg IV
over 1 minute followed by an infusion of 0.1-0.3 mg/kg/min)
-
Intravascular volume replacement may be necessary with adequate alpha
blockade. The amount is best determined by monitoring pulmonary wedge pressure.
B. Prolonged medical therapy
Patients who have had recent myocardial infarctions, evidence of catecholamine
cardiomyopathy, or metastatic pheochromocytoma might require prolonged medical
therapy. Patients who are in their last trimester of pregnancy are best managed
by maintaining alpha blockade followed by cesarean delivery and tumor removal.
Drug therapy includes the following:
-
Alpha blockers.
Dybenzyline (Phenoxybenzamine) 10 mg
bid
It is a long-acting alpha-adrenergic
blocker, can be given 10 mg bid initially and gradually increased by 10-20
mg/day to a total daily dose of 40-200 mg.
Prazosin, a selective alpha-1 blocker, is also effective, with
a usual required dosage of 1-2 mg bid or tid.
Terazosin (Hytrin) 1-10 mg/d PO
Doxazosin
-
Beta blockers are used after adequate alpha blockade is achieved.
Propranolol/ Inderal (20-40 mg q6h) is effective for
treatment of supraventricular arrhythmias.
Metoprolol/Lopressor, 50-100 mg, a relative cardioselective
beta blocker, is more appropriate in most patients.
-
Metyrosine, an inhibitor of tyrosine
hydroxylase, is used in patients whose condition is inoperable or in those
with metastatic malignant pheochromocytoma.
-
Medications such as labetalol, captopril, verapamil, and nifedipine
have been used successfully in selected situations. Combination therapy with
cyclophosphamide, vincristine, and dacarbazine can be used in advanced malignant
pheochromocytoma. Somatostatin has been used with success to control symptoms
in patients with metastatic pheochromocytomas producing vasoactive intestinal
polypeptide (VIP) and calcitonin.
In patients with malignant or unresectable disease, consider treatment
with tumor-directed non-drug therapy.
-
* Be aware that the only cure for malignant pheochromocytoma is complete
resection; resect metastatic lesions if possible.
-
* Treat painful skeletal metastatic lesions with external radiation therapy
or radiofrequency ablation.
-
* Note that radiofrequency ablation of hepatic and bone metastases may be
very effective in selected patients.
Drug Treatment for Pheochromocytoma:
Phenoxybenzamine
(Dybenzyline)
-
Initial dosage: 10 mg cap po bid, increased by 10-20 mg every 2-3 days prn
to control blood pressure and spells. Usual dose 20-100 mg/day
-
alpha-adrenergic blocking agent; irreversible and long-acting
-
Normotension and resolution of paroxysms
-
Postural hypotension, tachycardia, miosis, nasal congestion, diarrhea, inhibition
of ejaculation, and fatigue
-
Given in twice daily dosing, starting with 10 mg bid and titrated for normal
blood pressure and resolution of paroxysms; The effects of daily
administration are cumulative for nearly a week; ~25% of oral dose is absorbed
alpha-methyl-?-L-tyrosine (metyrosine)
-
Catecholamine synthesis inhibitor
-
1,000-4,000 mg/d; Available in 250-mg capsules; Initial dosage: 250
mg qid, titrated for normal blood pressure and resolution of paroxysms
-
Normotension and resolution of paroxysms
-
Sedation, depression, diarrhea, anxiety, nightmares, crystalluria and
urolithiasis, galactorrhea, and extrapyramidal manifestations
-
Use this agent with caution and only after other agents have been shown to
be ineffective. Especially useful for patients who, for cardiopulmonary reasons,
cannot be treated with combined ?- and ?-adrenergic blockade. The
extrapyramidal effects of phenothiazine or haloperidol may be potentiated,
and their concomitant use with metyrosine should be avoided. Ensure
high fluid intake to avoid crystalluria for any patient taking >2 g/d
Nicardipine
-
Calcium channel blocker
-
20-90 mg/d. Available as 30-, 45-, and 60-mg sustained-release capsules.
Initial dose: 30 mg (sustained-release capsule) once daily, titrated
prn for blood pressure control. To treat acute hypertensive crises:
starting dose is 2.5 µg/kg·min and titrated for blood pressure
control
-
Normotension and resolution of paroxysms
-
Edema, dizziness, headache, flushing, nausea, dyspepsia
Phentolamine
-
alpha-adrenergic blocking agent
-
1 mg IV test dose, then 2-5 mg IV boluses prn, or continuous infusion (100
mg in 500 mL 5% dextrose and water)
-
To treat acute hypertensive crises
-
Postural hypotension, tachycardia, miosis, nasal congestion, diarrhea, inhibition
of ejaculation, and fatigue
-
The response to phentolamine is 2-3 minutes maximum after a bolus injection
and lasts 10-15 minutes
Nitroprusside
-
Direct vasodilator
-
0.5-5.0 µg/kg·min (maximal dose should not exceed 800 µg/min)
-
To treat acute hypertensive crises
-
Nausea, vomiting. apprehension, headache, dizziness, restlessness, perspiration
palpitations, retrosternal discomfort, abdominal pain, muscle twitching (effects
may be reduced by slowing the infusion rate). Also, sodium nitroprusside
is metabolized rapidly to cyanide then thiocyanate. High plasma concentrations
of thiocyanate may occur if treatment is continued for several days and may
cause mental confusion, tinnitus, blurred vision, nausea, fatigue, ataxia,
and unconsciousness
Differential Diagnosis
of Pheochromocytoma
Thyrotoxicosis
-
Signs and symptoms of hyperthyroidism (unintended weight loss, increased
heart rate, tremor) and suppressed serum TSH concentration are present
-
Suppressed serum TSH and increased serum thyroxine are diagnostic, and symptoms
resolve with thyroid-directed treatment
Primary hypogonadism (e.g., menopausal
syndrome)
-
Hot flashes with facial flushing are typical. These episodes
are typically nocturnal, and gonadal replacement therapy is curative
-
The patient has low serum concentrations of gonadal steroid (e.g., estradiol
or testosterone) and increased serum concentrations of gonadotropins
Pancreatic tumors (e.g., insulinoma)
-
Patients with insulinoma typically have their symptoms (hunger, tremor,
agitation, diaphoresis, confusion) with fasting, and symptoms resolve with
eating
-
Whipple's triad: low plasma glucose concentration during the occurrence of
symptoms and relief of symptoms by the correction of hypoglycemia
Medullary thyroid carcinoma
-
Thyroid mass and increased serum concentration of calcitonin are evident.
Patients may have flushing and diarrhea
-
Markedly elevated serum calcitonin levels are diagnostic
"Hyperadrenergic" spells
-
This is a diagnosis of exclusion, and the signs and symptoms may be clinically
indistinguishable from patients with pheochromocytoma except that all
catecholamines and catecholamine metabolite levels are normal
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Essential hypertension - labile
-
Labile blood pressure is quite common and these patients have normal levels
of catecholamines and catecholamine metabolites
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Angina and cardiovascular deconditioning
-
Chest pain, palpitation, and diaphoresis are typically exertion-induced
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Dilated cardiomyopathy
-
Catecholamine-induced cardiomyopathy should be considered in all patients
with a dilated cardiomyopathy
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Syncope
-
Isolated syncope is a rare presentation of pheochromocytoma
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Orthostatic hypotension and autonomic neuropathy
-
Orthostasis is not unusual in patients with pheochromocytoma. Autonomic function
testing may be needed
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Paroxysmal cardiac arrhythmia
-
Palpitations are common in patients with pheochromocytoma
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Renovascular hypertension
-
Paroxysmal hypertension and symptoms can occur in patients with renovascular
disease
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Anxiety, panic attacks, and hyperventilation
-
Panic disorder symptoms are frequently confused with the presentation of
pheochromocytoma
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Withdrawal of adrenergic-inhibiting medications
(e.g., clonidine)
-
Clinical setting is usually diagnostic
-
Catecholamines and catecholamine metabolites levels may be temporarily increased
Monoamine oxidase inhibitor treatment and concomitant
ingestion of tyramine or a decongestant
-
Clinical setting is usually diagnostic
-
Catecholamines and catecholamine metabolites levels may be temporarily increased
Sympathomimetic ingestion
-
Clinical setting is usually diagnostic
-
Catecholamines and catecholamine metabolites levels may be temporarily increased
Illicit drug ingestion (e.g., cocaine, phencyclidine,
lysergic acid)
-
Clinical setting is usually diagnostic
-
Catecholamines and catecholamine metabolites levels may be temporarily increased
Postural orthostatic tachycardia syndrome (POTS)
-
Patients have posture-induced symptoms of lightheadedness and increased heart
rate
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Mastocytosis (systemic or activation disorder)
-
Typically presents with flushing and hypotension. Evaluation with urinary
methylhistamine and serum tryptase is diagnostic
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Carcinoid syndrome
-
Typically presents with flushing, diarrhea, and cardiac-related symptoms.
24-hour urinary excretion of 5-hydroxyindole acetic acid is diagnostic
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Recurrent idiopathic anaphylaxis
-
Patients present with sudden onset of multiple symptoms that may include:
hypotension, dyspnea, urticaria, palpitation, pallor, and syncope
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
Unexplained flushing spells
-
This is a diagnosis of exclusion and the signs and symptoms may be clinically
indistinguishable from patients with pheochromocytoma except that all
catecholamines and catecholamine metabolite levels are normal
-
Normal levels of catecholamines and catecholamine metabolites exclude
pheochromocytoma as the cause
REF:
ACP - PIER 2004
Ann Intern Med. 20 Feb. 2001;134:315-329 (NIH Conference)
122004